Menu ×

HEALTHCARE & PHARMACEUTICAL

Microbiome Therapeutics Market Segmentation by Application {Diabetes, Crohn’s Disease, Clostridium Difficile Infection (CDI), Multiple Sclerosis, Rheumatoid Arthritis, and Others} - Global Demand Analysis & Opportunity Outlook 2029

  • Text Size:

Extensive insights into the Growth of Microbiome Therapeutics Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • February 19, 2020: DuPont Nutrition & Biosciences announced that it has collaborated with a biopharmaceutical company, MRM Health NV for developing innovative microbiome-based therapeutics.

Introduction to Microbiome Therapeutics

Microbiome is defined as the genetic material of all the microorganisms, such as bacteria, protozoa, viruses and fungi, that live on and inside the human body. Microbiome therapeutics is the process of restoring healthy gut microbiota inside the human body. In the human body, microorganisms reside in saliva, oral mucosa, conjunctiva, gastrointestinal tract (GIT) and even on the skin. These microorganisms are beneficial for human beings as it helps to balance good health. The study of microbiome has fascinated researchers remarkably and has gained huge significance post the research initiatives taken by the National Institutes of Health (NIH) of the United States with their research project “The Human Microbiome Project (HMP)”, established in the year 2007 through 2016.

Market Size and Forecast

The global microbiome therapeutics market is thriving primarily on account of the growing prevalence of diseases caused due to dysbiosis of microbiota in the gut, along with the growing concerns amongst individuals for the reducing number of beneficial microorganisms in the human body, impacted by the long-term use of antibiotics, growing age and unhealthy lifestyle patterns. The global microbiome therapeutics market is anticipated to grow with a notable CAGR during the forecast period, i.e., 2021-2029. The market is segmented by application into diabetes, Crohn’s disease, clostridium difficile infection (CDI), multiple sclerosis, rheumatoid arthritis, and others. Among these segments, the diabetes segment is anticipated to hold the largest share by the end of 2029 owing to the increasing prevalence of diabetes around the globe, coupled with the growing research and developments on the use of microbiome therapeutics for curing type 2 diabetes. According to the statistics by the Centers for Disease Control and Prevention (CDC), in the year 2018, around 10.5% of the population of the United States had diabetes. Studies have reflected that the gut bacteria play a fundamental role in diseases such as diabetes, especially type 2 diabetes. Type 2 diabetes is largely undiagnosed and is caused due to excessive body weight and physical inactivity. Research on the first human metagenome demonstrated the correlation between certain bacterial genes, specific intestinal bacteria and their respective metabolic pathways with type 2 diabetes (T2D).

Microbiome-Therapeutics-Market

Growth Drivers

Growing Need for Early Detection and Diagnosis of Diseases

Early detection and diagnosis of critical diseases in patients helps to increase the survival rate of the patients. As the presumptive identification of diseases plays a major role in saving lives, researchers are increasingly working on to develop medicines and diagnostics processes that help to detect diseases early. Moreover, with the growing incidences of chronic diseases, such as diabetes, Crohn’s disease, clostridium difficile infection (CDI), multiple sclerosis, and others, there is a rising need amongst individuals for the early detection of these diseases, which is raising the need amongst the researchers to research on advanced biological processes by using technologies, such as microbiome therapeutics, which can be designed for use as a validated target for drug development. CLICK TO DOWNLOAD SAMPLE REPORT

Increasing Investments for Research and Development of Microbiome Therapeutics

Over the decades, governmental organizations with the support of the Nations, are investing a significant share of their GDP for the research and development of novel drugs. The private healthcare organizations along with the support of the governmental bodies, on the other hand, have developed dedicated team of researchers, who have developed novel drugs and vaccines over the years. Projects such as the HMP have opened the face for the advanced studies on diseases which were once thought to be impossible. Such factors are anticipated to drive the growth of the global microbiome therapeutics market in the coming years.

Challenges

The research processed by numerous organizations on microbiome therapeutics are currently under different phases of clinical development. Organizations have invested massively in these research processes over the years with hopes for success on their efforts. Yet, the concerns for the failure of the research projects, which would significantly impact their research investments is one of the major factors anticipated to hamper the market growth during the forecast period.

Market Segmentation

Our in-depth analysis of the global microbiome therapeutics market includes the following segments:

By Application

  • Diabetes
  • Crohn’s Disease
  • Clostridium Difficile Infection (CDI)
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Others

By Region

On the basis of regional analysis, the global microbiome therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa regions.

The market for microbiome therapeutics in North America is anticipated to hold the largest market share during the forecast period on account of the presence of numerous established research facilities in the region for the development of novel therapeutics, followed by the rising healthcare expenditure and the presence of a population who are highly conscious with their health. Additionally, presence of several key players in the region, along with the favorable government initiatives for research and development, are some of the factors anticipated to drive the growth of the market in the region.

The global microbiome therapeutics market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved